COVID Articles
A study has found that for patients with certain types of advanced lung or skin cancer, administration of a SARS-CoV-2 mRNA vaccine within 100 days of starting immune checkpoint inhibitors is associated with increased overall survival.
A new study has found people have an increased risk of major cardiovascular events following viral infections such as SARS-CoV-2, influenza, HIV, hepatitis C and varicella zoster virus.
Since the U.S. Food and Drug Administration released its 2025-2026 formula approvals on Aug. 2, significantly restricting who can access the vaccines for the first time since their release, several states have issued their own guidance about COVID-19 vaccines.
Pfizer and BioNTech updated mRNA COVID-19 vaccine for the 2025-2026 season produced strong immune responses, boosting neutralizing antibody levels by at least fourfold in older people and those with underlying medical conditions.
The U.S. Food and Drug Administration may revoke Pfizer-BioNTech’s emergency use authorization for its COVID-19 vaccine, Comirnaty, for children ages 6 months through 4 years.
The U.S. Food and Drug Administration (FDA) has granted full approval for Moderna’s Spikevax (mRNA-1273) COVID vaccine in children 6 months through 11 years who are at an increased risk of the disease.
A recent study found there is significantly higher intravenous immune globulin (IVIG) resistance among children who contracted COVID-19 before developing Kawasaki disease
Moderna’s experimental mRNA-based influenze (flu) vaccine produced a stronger immune response than a currently available vaccine in a late-stage trial, clearing a path forward for the product and the company’s separate combination flu and COVID vaccine.
In a late-stage trial, Novavax's experimental COVID-19-influenza combination (CIC) and standalone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) vaccines generated a strong immune response in adults aged 65 and older, similar to already approved vaccines against the viruses.
After a six-week delay, the U.S. Food and Drug Administration approved Novavax’s COVID-19 vaccine, but only for people 65 and older and those 12 years and older who have at least one underlying condition, such as asthma, diabetes, lung disease, obesity and pregnancy, that puts them at higher risk of severe illness.
A recent study of Moderna’s combination influenze (flu) and COVID-18 vaccine, mRNA-1083, found that it induced higher immune responses than recommended standard care influenza (standard and high dose) and COVID-19 vaccines against all four influenza strains (among those ages 50 to 64 years), the three clinically relevant influenza strains (among those aged 65 years and older), and SARS-CoV-2 (all ages), with an acceptable tolerability and safety profile.
A recent study found there is significantly higher intravenous immune globulin (IVIG) resistance among children who contracted COVID-19 before developing Kawasaki disease (KD).